SPRYARS Pharmaceuticals Inc. Common Stock
5.505USD-13.71%Mkt Cap: 547.46M $P/E: —3d ago
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap547.46M $
Enterprise Value575.22M $
Revenue (TTM)116.93M $
Gross Profit63.85M $
Net Income (TTM)-171.30M $
Revenue/Share1.180 USD
Last Price5.505 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees195
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.19
PEG—
EV/EBITDA-2.68
EV/Revenue4.92
P/S4.68
P/B43.69
EPS (TTM)-1.88
EPS (Forward)-0.89
52W Range
4.9106% of range15.09
52W High15.09 USD
52W Low4.910 USD
Profitability
Gross Margin75.77%
Oper. Margin-182.62%
EBITDA Margin-183.57%
Profit Margin-203.25%
ROE-149.92%
ROA-52.28%
Growth
Revenue Growth114.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-170.87M $
CapEx (TTM)339.00K $
FCF Margin-100.66%
FCF Yield-21.50%
Net Debt27.76M $
Net Debt/EBITDA-0.13
Balance Sheet
Debt/Equity0.84
Current Ratio3.48
Quick Ratio3.15
Book Value/Sh0.1260 USD
Cash/Share1.446 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.25 USD
Upside (mean)+322.3%
Target Range17.00 USD – 30.00 USD
$17.00+322.3% to mean$30.00
# Analysts4
Ownership
Shares Out.99.45M
Float48.03M
Insiders16.18%
Institutions92.07%
Short Interest
Short Ratio9.8d
Short % Float31.17%
Short % Out.21.60%
Shares Short21.45M
Short (prev mo.)21.73M
Technical
SMA 507.333 (-24.9%)
SMA 2008.717 (-36.8%)
Beta0.97
S&P 52W Chg18.16%
Avg Vol (30d)2.22M
Avg Vol (10d)2.10M
Technical Indicators
RSI (14)39.8
MACD-0.3391
MACD Signal-0.4677
MACD Hist.+0.1286
BB Upper6.446 USD
BB Middle5.780 USD
BB Lower5.114 USD
BB Width23.05%
ATR (14)0.5100 USD
Vol Ratio (20d)0.54x